

MSM Protein Technologies Announces the Appointment of Dr. Christopher Hentschel to the Board of Directors

05/25/2010

MSM Protein Technologies Announces the Appointment of Dr. Christopher Hentschel to the Board of Directors

Chris Hentschel, PhD., has joined the Board of MSM Protein Technologies. Dr. Hentschel has extensive industry experience. He has served as the original President and CEO of the Malaria Medical Venture (MMV) over the past 10 years, growing the non-profit into a world-class portfolio for the treatment of malaria. Prior to his work at MMV, Chris Hentschel was the Chief Scientific Officer at Centocor before it merged with Johnson and Johnson. Dr. Hentschel was also the founding head of the Collaborative Centre of the UK Medical Research Council in London. His expertise in developing pharmaceutical research projects from start-ups to industry leaders will provide invaluable insight in his role as MSM's first outside Director.

About MSM Protein Technologies

MSM Protein Technologies is a closely held drug discovery company based in Medford, MA. The company specializes in discovering fully human, functional antibodies targeting complex cell surface receptors such as GPCR's. Using its proprietary SIMPL™ platform and magnetic proteoliposome particles (MPLs), MSM is able to display multispanspan membrane proteins such as GPCRs in a highly concentrated and purified form while retaining their native conformation and orientation. These technologies, originating at the Dana Farber Cancer institute and developed at MSM, allow the company to maximize the probability of discovering functional antibodies.

For more information: info@msmprotein.com 781-321-3322

